NASDAQ
CALT

Calliditas Therapeutics

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Calliditas Therapeutics Stock Price

Vitals

Today's Low:
$15.26
Today's High:
$16.19
Open Price:
$15.64
52W Low:
$10.82
52W High:
$25.64
Prev. Close:
$15.745
Volume:
7889

Company Statistics

Market Cap.:
$468.82 million
Book Value:
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$787.68 million
Profit Margin:
-41.58%
Return on Assets TTM:
-14.76%
Return on Equity TTM:
-53.78%

Company Profile

Calliditas Therapeutics had its IPO on 2020-06-05 under the ticker symbol CALT.

The company operates in the Healthcare sector and Biotechnology industry. Calliditas Therapeutics has a staff strength of 181 employees.

Stock update

Shares of Calliditas Therapeutics opened at $15.64 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $15.26 - $16.19, and closed at $16.18.

This is a +2.76% increase from the previous day's closing price.

A total volume of 7,889 shares were traded at the close of the day’s session.

In the last one week, shares of Calliditas Therapeutics have slipped by -1.31%.

Calliditas Therapeutics's Key Ratios

Calliditas Therapeutics has a market cap of $468.82 million, indicating a price to book ratio of 7.3857 and a price to sales ratio of 13.2379.

In the last 12-months Calliditas Therapeutics’s revenue was $0 with a gross profit of $787.68 million and an EBITDA of $0. The EBITDA ratio measures Calliditas Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Calliditas Therapeutics’s operating margin was 0% while its return on assets stood at -14.76% with a return of equity of -53.78%.

In Q4, Calliditas Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 284.8%.

Calliditas Therapeutics’s PE and PEG Ratio

Forward PE
8.7719
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.47 per share while it has a forward price to earnings multiple of 8.7719 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Calliditas Therapeutics’s profitability.

Calliditas Therapeutics stock is trading at a EV to sales ratio of 1.2248 and a EV to EBITDA ratio of -0.7534. Its price to sales ratio in the trailing 12-months stood at 13.2379.

Calliditas Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.95 billion
Total Liabilities
$325.23 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Calliditas Therapeutics ended 2024 with $1.95 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.95 billion while shareholder equity stood at $766.26 million.

Calliditas Therapeutics ended 2024 with $0 in deferred long-term liabilities, $325.23 million in other current liabilities, 2383000.00 in common stock, $-1827010000.00 in retained earnings and $45.80 million in goodwill. Its cash balance stood at $1.25 billion and cash and short-term investments were $1.25 billion. The company’s total short-term debt was $0 while long-term debt stood at $713.03 million.

Calliditas Therapeutics’s total current assets stands at $1.41 billion while long-term investments were $11.21 million and short-term investments were $0. Its net receivables were $159.46 million compared to accounts payable of $160.40 million and inventory worth $3.65 million.

In 2024, Calliditas Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Calliditas Therapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$16.18
52-Week High
$25.64
52-Week Low
$10.82
Analyst Target Price
$51.8

Calliditas Therapeutics stock is currently trading at $16.18 per share. It touched a 52-week high of $25.64 and a 52-week low of $25.64. Analysts tracking the stock have a 12-month average target price of $51.8.

Its 50-day moving average was $17.27 and 200-day moving average was $19.4 The short ratio stood at 1.3 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 357.4% are held by institutions.

Frequently Asked Questions About Calliditas Therapeutics

The stock symbol (also called stock or share ticker) of Calliditas Therapeutics is CALT

The IPO of Calliditas Therapeutics took place on 2020-06-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.04
-0.01
-0.95%
$0.06
-0.01
-12.86%
C3 Ai Inc (AI)
$28.1
-0.12
-0.43%
$136.95
-8.3
-5.71%
Fabrinet (FN)
$148.8
-3.26
-2.14%
$29.7
-0.6
-1.98%
$0.36
-0.01
-1.38%
$13.64
0.21
+1.56%
RARPS (RARPS)
$1.2
-1.05
-46.67%
$63.66
0.7
+1.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company’s lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Address

Kungsbron 1, D5, Stockholm, Sweden, 111 22